Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Call Transcript

Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 AM ET

Company Participants

Susan Ringdal – EVP, Strategic Planning and Global Affairs

Said Darwazah – Chief Executive Officer

Brian Hoffmann – President of Generics

Riad Mishlawi – President of Injectables

Mazen Darwazah – Vice Chairman of Hikma and Head of the Branded Business

Khalid Nabilsi – Chief Financial Officer

Guy Featherstone – Associate Director, Investor Relations

Conference Call Participants

Peter Verdult – Citi

Thibault Boutherin – Morgan Stanley

Paul Cuddon – Numis

Emily Field – Barclays

James Gordon – JPMorgan

Harry Sephton – Credit Suisse

Christian Glennie – Stifel

Victoria Lambert – Berenberg

Susan Ringdal

Good morning everyone, and thank you for joining Hikma’s results Q&A today. Hopefully, you have all been able to download our prerecorded presentation from hikma.com. I’m very pleased to have our Hikma management team here with us today. We’re joined by our CEO, Said Darwazah; our CFO, Khalid Nabilsi; Vice Chairman of Hikma and Head of the Branded business, Mazen Darwazah; the President of Injectables, Riad Mishlawi; and the President of Generics, Brian Hoffmann.

With no further ado, I will pass the call over to Said.

Said Darwazah

Thank you, Susan, and good morning, everybody. I’m sure you’ve already – or I hope you’ve already read the releases. I’m extremely happy with the results this year. In a very relatively tough year, we have delivered resilient results. Our top line is almost the same as last year, and the core operating profit is down about 6%. And when you consider the extra interest rates that we paid the shipping, the fuel, the inflation and so on, it really shows that the company delivered very good and very resilient results.

The Injectables and Branded businesses, of course, have done extremely well. They were able to

Source link

#Hikma #Pharmaceuticals #PLC #HKMPF #Earnings #Call #Transcript

Leave a Reply

Your email address will not be published. Required fields are marked *